Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $30.7 million.

  • Dare Bioscience's Liabilities and Shareholders Equity rose 7026.92% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.4 million, marking a year-over-year increase of 1117.46%. This contributed to the annual value of $22.1 million for FY2024, which is 384.79% up from last year.
  • Per Dare Bioscience's latest filing, its Liabilities and Shareholders Equity stood at $30.7 million for Q3 2025, which was up 7026.92% from $13.0 million recorded in Q2 2025.
  • Over the past 5 years, Dare Bioscience's Liabilities and Shareholders Equity peaked at $55.8 million during Q4 2021, and registered a low of $10.5 million during Q1 2021.
  • Over the past 5 years, Dare Bioscience's median Liabilities and Shareholders Equity value was $23.6 million (recorded in 2024), while the average stood at $29.7 million.
  • In the last 5 years, Dare Bioscience's Liabilities and Shareholders Equity surged by 63909.82% in 2021 and then plummeted by 5714.8% in 2024.
  • Over the past 5 years, Dare Bioscience's Liabilities and Shareholders Equity (Quarter) stood at $55.8 million in 2021, then decreased by 21.47% to $43.8 million in 2022, then crashed by 51.44% to $21.3 million in 2023, then grew by 3.85% to $22.1 million in 2024, then surged by 39.13% to $30.7 million in 2025.
  • Its Liabilities and Shareholders Equity was $30.7 million in Q3 2025, compared to $13.0 million in Q2 2025 and $18.6 million in Q1 2025.